Making stem cells to create insulin-producing pancreatic beta cells
Official title: Production Of Induced Pluripotent Stem Cells (iPSCs) For The Generation Of Insulin-Producing β Cells
Run by Ospedale San Raffaele · NCT07479134 · Data updated 2026-11-12
This project will try to turn a small skin, blood, or urine sample from people with diabetes and healthy volunteers into stem cells that can be made into insulin-producing pancreatic beta cells.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 12 Years to 70 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Ospedale San Raffaele Academic / other |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | March 1, 2026 |
| Main results expected | February 28, 2035 |
| Study ends | February 28, 2036 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT07479134 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are people aged 12–70 with pancreatic β cell disorders (such as type 1 or type 2 diabetes, MODY, Wolfram syndrome, or pancreatogenic diabetes) or healthy volunteers willing to provide a one-time skin, blood, or urine sample and informed consent.
✕Probably not a fit
People with active cancer, known HIV/HBV/HCV infection, severely unstable blood glucose at sampling, or on medications that interfere with iPSC generation are excluded and are unlikely to benefit from participating.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Participants provide a one-time biological sample (3 mm skin punch biopsy, blood draw, or urine) collected at Ospedale San Raffaele in Milan. Somatic cells from those samples will be reprogrammed into induced pluripotent stem cells (iPSCs) and then differentiated in the lab into insulin-producing β cells. Researchers will compare iPSC-derived β cells from patients with metabolic or genetic pancreatic disorders (including type 1 and type 2 diabetes, MODY, Wolfram syndrome, and pancreatogenic diabetes) to cells from healthy donors to identify disease-specific cellular and molecular features. The primary aim is to establish a reliable, reproducible protocol for producing functional β cells to support disease modeling and future cell-based therapies.
Why it matters
Potential benefit: If successful, this work could provide patient-specific beta cells for lab research and help lay the groundwork for future cell-replacement therapies for diabetes.
How similar studies have gone: Similar laboratory programs have successfully generated iPSC-derived insulin-producing cells for disease modeling, but translating these results into safe, effective cell therapies for patients remains experimental.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Age between 12 and 70 years. Ability and willingness to provide informed consent (or assent with parental consent for minors). Group 1: Individuals diagnosed with pancreatic β cell dysfunction, including but not limited to: Type 1 Diabetes Type 2 Diabetes Maturity Onset Diabetes of the Young (MODY) Wolfram Syndrome Pancreatogenic Diabetes Group 2: Healthy control donors without pancreatic β cell dysfunction. Pregnant or breastfeeding women may be included if they meet the inclusion criteria. Exclusion Criteria: Age below 12 or above 70 years. Health condition too compromised to allow safe tissue collection (e.g., acute hypoglycemia \<70 mg/dL or hyperglycemia \>140 mg/dL at sampling). Inability or unwillingness to provide informed consent/assent. Active malignancy or current cancer treatment. Known infection with HIV, Hepatitis B, or Hepatitis C. Use of medications that may interfere with iPSC generation (e.g., high-dose corticosteroids, immunomodulators), unless approved by investigators. For participants undergoing skin biopsy: bleeding disorders, local skin infection, allergy to anesthetics, or use of anticoagulants.
Where it's running
-
Diabetes Research Institute
Milan, Italy Recruiting
Study contacts
- Study coordinator: Valeria Sordi, PhD
- Email: sordi.valeria@hsr.it
- Phone: +390226432643
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
New virtual care pathway for older adults with chronic diseases
A teleconsultation-based care pathway for adults 60+ with hypertension, diabetes, or dyslipidemia to see if it’s feasible and cost-saving in Malaysian primary care compared with usual clinic visits.
-
Benefits of Retained Insulin for Good Health in Diabetes
This study tests whether preserving or restoring a person’s own insulin production can improve quality of life and blood sugar control for people who need insulin to manage diabetes.
-
Improving Care for underserved older Black patients with cardiovascular and other chronic conditions
This study tests a culturally tailored approach to patient-centered care for older African American patients with cardiovascular disease and other conditions who receive care at a community hospital.
-
Myokines in metabolic and endocrine diseases linked to sarcopenia
This study tests whether myokines can serve as biomarkers or drivers of sarcopenia and sarcopenic obesity in people with metabolic or endocrine diseases.
-
Miniature breath sensors to detect hypo- and hyperglycemia in young people with diabetes
A small breath-sensor device will try to see if specific breath compounds can signal low or high blood sugar in youths with diabetes.
-
Polypill Approach for Multiple Cardiovascular Risk Factors
Researchers are testing a fixed-dose pill strategy to help people aged 50–75 with high blood pressure, high cholesterol, and diabetes see if it lowers their heart-disease risk and reduces future events.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.